Drug delivery strategies that use anti-transferrin receptor antibodies have shown increased drug brain penetration in models of neurodegenerative diseases and brain tumors (Lajoie and Shusta, 2015; Wang et al., 2015). This evidence concerns the gene TFRC and neurodegenerative disease.